The hypothalamic paraventricular nucleus is a site of action for the central effect of tachykinins on plasma vasopressin.
The intracerebroventricular injection of eledoisin (ELE), or of other tachykinins with potent agonist activity at neurokinin B (NK-3) receptors, increases plasma vasopressin in the rat. The effect is antagonized by saralasin pretreatment, thus suggesting that it is mediated by angiotensin receptor activation. Since the magnocellular part of the hypothalamic paraventricular nucleus (PVN) is very rich in NK-3 receptors, the present study was aimed at investigating the role of this nucleus in the effect of ELE on plasma vasopressin. Direct injection of ELE into the PVN increased plasma vasopressin levels more potently than the injection of the same doses into the lateral ventricle. Lesioning of the magnocellular part of the PVN completely abolished the increase in plasma vasopressin induced by the injection of ELE 100 ng/rat into the lateral ventricle. Pretreatment into the PVN either with saralasin or with captopril resulted in a marked suppression of the effect of ELE on plasma vasopressin. These findings indicate the PVN as a site of action for the central effect of tachykinins on plasma vasopressin and suggest that the angiotensin mediation of the effect might take place in the same nucleus.
Massi
M
M
Istituto di Farmacologia, Facoltà di Farmacia, Università di Camerino, Italy.
Saija
A
A
Polidori
C
C
Perfumi
M
M
Gentili
L
L
Costa
G
G
de Caro
G
G
D000595:Amino Acid Sequence; D000818:Animals; D002216:Captopril / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D008969:Molecular Sequence Data; D010286:Paraventricular Hypothalamic Nucleus / Q000187:drug effects*; D051381:Rats; D011919:Rats, Inbred Strains; D012504:Saralasin / Q000494:pharmacology; D015320:Tachykinins / Q000494:pharmacology*; D014667:Vasopressins / Q000097:blood / Q000187:drug effects*
D015320:Tachykinins; D014667:Vasopressins; D002216:Captopril; D012504:Saralasin